NFKB1 and neoplasm: Crucially, our findings convincingly demonstrate that blocking GNA13-induced MAPK/AP-1 and/or NFκB signaling can indeed be a strategy to target TIC-induced tumor growth and therapeutic resistance in solid tumors that express high amounts of GNA13.